Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection

Farmaco

Volumn 54, Issue 1-2, 1999, Pages 26-45

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Delavirdine; HIV; Nevirapine; NNRTIs (non nucleoside reverse transcriptase inhibitors); Reverse transcriptase; Triple drug combinations

Indexed keywords

3 [(4,7 DICHLORO 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; 6 CHLORO 4 CYCLOPROPYL 3,4 DIHYDRO 4 [(2 PYRIDYL)ETHYNYL] 2(1H) QUINAZOLINONE; CAPRAVIRINE; DELAVIRDINE; EFAVIRENZ; EMIVIRINE; LAMIVUDINE; LOVIRIDE; MEN 10979; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; NSC 287474; NSC 625487; PETT 4; PETT 5; PROTEINASE INHIBITOR; RD 4 2024; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TALVIRALINE; TIVIRAPINE; TROVIRDINE; UK 129485; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

BINDING SITE; CLINICAL TRIAL; DRUG DESIGN; DRUG LEGISLATION; DRUG PROTEIN BINDING; DRUG RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; RASH; REVIEW; VIRUS INHIBITION; VIRUS REPLICATION;

HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MODELS, MOLECULAR; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0032918170     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(98)00103-7     Document Type: Review

References (157)

1. De Clercq E. Antiviral threapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. 8:1995;200-239.
2. De Clercq E. In search of a selective antiviral chemotherapy. Clin. Microbiol. Rev. 10:1997;674-693.
3. De Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. Med. Res. Rev. 16:1996;125-157.
4. De Clercq E. What can be expected from non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the treatment of human immunodeficiency virus type 1 (HIV-1) infections? Rev. Med. Virol. 6:1996;97-117.
5. Baba M., Tanaka H., De Clercq E., Pauwels R., Balzarini J., Schols D., Nakashima H., Perno C-F., Walker R.T., Miyasaka T. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem. Biophys. Res. Commun. 165:1989;1375-1381.
6. Miyasaka T., Tanaka H., Baba M., Hayakawa H., Walker R.T., Balzarini J., De Clercq E. A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J. Med. Chem. 32:1989;2507-2509.
7. Pauwels R., Andries K., Desmyter J., Schols D., Kukla M.J., Breslin H.J., Raeymaeckers A., Van Gelder J., Woestenborghs R., Heykants J., Schellekens K., Janssen M.A.C., De Clercq E., Janssen P.A.J. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature. 343:1990;470-474.
8. Debyser Z., Pauwels R., Andries K., Desmyter J., Kukla M., Janssen P.A.J., De Clercq E. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidaz[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione derivatives. Proc. Natl. Acad. Sci. USA. 88:1991;1451-1455.
9. Baba M., De Clercq E., Tanaka H., Ubasawa M., Takashima H., Sekiya K., Nitta I., Umezu K., Nakashima H., Mori S., Shigeta S., Walker R.T., Miyasaka T. Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. USA. 88:1991;2356-2360.
10. Baba M., De Clercq E., Tanaka H., Ubasawa M., Takashima H., Sekiya K., Nitta I., Umezu K., Walker R.T., Mori S., Ito M., Shigeta S., Miyasaka T. Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives. Mol. Pharmacol. 39:1991;805-810.
11. Merluzzi V.J., Hargrave K.D., Labadia M., Grozinger K., Skoog M., Wu J.C., Shih C.-K., Eckner K., Hattox S., Adams J., Rosenthal A.S., Faanes R., Eckner R.J., Koup R.A., Sullivan J.L. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 250:1990;1411-1413.
12. Koup R.A., Merluzzi V.J., Hargrave K.D., Adams J., Grozinger K., Eckner R.J., Sullivan J.L. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. J. Infect. Dis. 163:1991;966-970.
13. Goldman M.E., Nunberg J.H., O'Brien J.A., Quintero J.C., Schleif W.A., Freund K.F., Gaul S.L., Saari W.S., Wai J.S., Hoffman J.M., Anderson P.S., Hupe D.J., Emini E.A., Stern A.M. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Natl. Acad. Sci. USA. 88:1991;6863-6867.
14. Goldman M.E., O'Brien J.A., Ruffing T.L., Nunberg J.H., Schleif W.A., Quintero J.C., Siegl P.K.S., Hoffman J.M., Smith A.M., Emini E.A. L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro. Antimicrob. Agents Chemother. 36:1992;1019-1023.
15. Romero D.L., Busso M., Tan C.-K., Reusser F., Palmer J.R., Poppe S.M., Aristoff P.A., Downey K.M., So A.G., Resnick L., Tarpley W.G. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA. 88:1991;8806-8810.
16. Romero D.L., Morge R.A., Genin M.J., Biles C., Busso M., Resnick L., Althaus I.W., Reusser F., Thomas R.C., Tarpley W.G. Bis(heteoaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)carbonyl]-4-[3-[(1-methylethyl)amino] pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate. J. Med. Chem. 36:1993;1505-1508.
17. Balzarini J., Pérez-Pérez M.-J., San-Félix A., Schols D., Perno C.-F., Vandamme A.-M., Camarasa M.-J., De Clercq E. 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro- 5′′(4′′-amino-1′′,2′′-oxathiole- 2′′,2′′-dioxide)pyrimidine (TSAO) nucleoside analogues: novel highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc. Natl. Acad. Sci. USA. 89:1992;4392-4396.
18. Balzarini J., Perez-Perez M.-J., San-Felix A., Velazquez S., Camarasa M.-J., De Clercq E. 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro- 5′′-(4′′-amino-1′′,2′′-oxathile- 2′′,2′′-dioxide) (TSAO) derivatives of purine and pyrimidine nucleosides as potent and selective inhibitors of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 36:1992;1073-1080.
19. Balzarini J., Pérez-Pérez M.-J., San-Félix A., Camarasa M.-J., Barr P.J., De Clercq E. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]- 3′-spiro-5′′-(4′′-amino-1′′, 2′′-oxathiole-2′′,2′′-dioxide)thymine (TSAO-T). J. Biol. Chem. 267:1992;11831-11838.
20. Pauwels R., Andries K., Debyser Z., Van Daele P., Schols D., Stoffels P., De Vreese A., Woestenborghs R., Vandamme A.-M., Janssen C.G.M., Anné J., Cauwenbergh G., Desmyter J., Heykants J., Janssen M.A.C., De Clercq E., Janssen P.A.J. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. USA. 90:1993;1711-1715.
21. Ahgren C., Backro K., Bell F.W., Cantrell A.S., Clemens M., Colacino J.M., Deeter J.B., Engelhardt J.A., Högberg M., Jaskunas S.R., Johansson N.G., Jordan C.L., Kasher J.S., Kinnick M.D., Lind P., Lopez C., Morin J.M. Jr., Muesing M.A., Noreen R., Öberg B., Paget C.J., Palkowitz J.A., Parrish C.A., Pranc P., Rippy M.K., Rydergard C., Sahlberg C., Swanson S., Ternansky R.J., Unge T., Vasileff R.T., Vrang L., West S.J., Zhang H., Zhou X.-X. The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39:1995;1329-1335.
22. Baba M.M., Shigeta S., Yuasa S., Takashima H., Sekiya K., Ubasawa M., Tanaka H., Miyasaka T., Walker R.T., De Clercq E. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 38:1994;688-692.
23. Pauwels R., Andries K., Debyser Z., Kukla M.-J., Schols D., Breslin H.J., Woestenborghs R., Desmyter J., Janssen M.A.C., De Clercq E., Janssen P.A.J. New tetrahydroimidazo[4,5-1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2′,3′-dideoxynucleoside analogs. Antimicrob. Agents Chemother. 38:1994;2863-2870.
24. Danel K., Larsen E., Pedersen E.B., Vestergaard B.F., Nielsen C. Synthesis and potent anti-HIV-1 activity of novel 6-benzyluracil analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J. Med. Chem. 39:1996;2427-2431.
25. Dueweke T.J., Poppe S.M., Romero D.L., Swaney S.M., So A.G., Downey K.M., Althaus I.W., Reusser F., Busso M., Resnick L., Mayers D.L., Lane J., Aristoff P.A., Thomas R.C., Tarpley W.G. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 37:1993;1127-1131.
26. Zhang H., Vrang L., Backbro K., Lind P., Sahlberg C., Unge T., Öberg B. Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127. Antiviral Res. 28:1995;331-342.
27. Bell F.W., Cantrell A.S., Högberg M., Jaskunas S.R., Johansson N.G., Jordan C.L., Kinnick M.D., Lind L., Morin J.M. Jr., Noréen R., Öberg B., Palkowitz J.A., Parrish C.A., Pranc P., Sahlberg C., Ternansky R.J., Vasileff R.T., Vrang L., West S.J., Zhang H., Zhou X.-X. Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs. J. Med. Chem. 38:1995;4929-4936.
28. Balzarini J., Brouwer W.G., Felauer E.E., De Clercq E., Karlsson A. Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains. Antiviral Res. 27:1995;219-236.
29. Buckheit R.W. Jr., Snow M.J., Fliakas-Boltz V., Kinjerski T.L., Russell J.D., Pallansch L.A., Brouwer W.G., Yang S.S. Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates. Antimicrob. Agents Chemother. 41:1997;831-837.
30. Kleim J.-P., Bender R., Billhardt U.-M., Meichsner C., Riess G., Rösner M., Winkler I., Paessens A. Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob. Agents Chemother. 37:1993;1659-1664.
31. Kleim J.-P., Bender R., Kirsch R., Meichsner C., Paessens A., Rösner M., Rübsamen-Waigmann H., Kaiser R., Wichers M., Schneweis K.E., Winkler I., Riess G. Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 39:1995;2253-2257.
32. Buckheit R.W. Jr., Hollingshead M.G., Germany-Decker J., White E.L., McMahon J.B., Allen L.B., Ross L.J., Decker W.D., Westbrook L., Shannon W.M., Weislow O., Bader J.P., Boyd M.R. Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonucleoside reverse transcriptase inhibitor. Antiviral Res. 21:1993;247-265.
33. Chimirri A., Grasso S., Molica C., Monforte A.-M., Monforte P., Zappalà M., Bruno G., Nicolò F., Witvrouw M., Jonckheere H., Balzarini J., De Clercq E. Structural features and anti-human immunodeficiency virus (HIV) activity of the isomers of 1-(2′,6′-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Antiviral Chem. Chemother. 8:1997;363-370.
34. Mertens A., Zilch H., Konig B., Schafer W., Poll T., Kampe W., Seidel H., Leser U., Leinert H. Selective non-nucleoside HIV-1 reverse transcriptase inhibitors. New 2,3-dihydrothiazolo[2,3-a]isoindol-5(9H)-ones and related compounds with anti-HIV-1 activity. J. Med. Chem. 36:1993;2526-2535.
35. Maass G., Immendoerfer U., Koenig B., Leser U., Mueller B., Goody R., Pfaff E. Viral resistance to the thiazolo-iso-indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:1993;2612-2617.
36. Williams T.M., Ciccarone T.M., MacTough S.C., Rooney C.S., Balani S.K., Condra J.H., Emini E.A., Goldman M.E., Greenlee W.J., Kauffman L.R., O'Brien J.A., Sardana V.V., Schleif W.A., Theoharides A.D., Anderson P.S. 5-Chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase. J. Med. Chem. 36:1993;1291-1294.
37. Buckheit R.W. Jr., Fliakas-Boltz V., Decker W.D., Roberson J.L., Pyle C.A., White E.L., Bowdon B.J., McMahon J.B., Boyd M.R., Bader J.P., Nickell D.G., Barth H., Antonucci T.K. Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors. Antiviral Res. 25:1994;43-56.
38. Tucker T.J., Lyle T.A., Wiscount C.M., Britcher S.F., Young S.D., Sanders W.M., Lumma W.C., Goldman M.E., O'Brien J.A., Ball R.G., Homnick C.F., Schleif W.A., Emini E.A., Huff J.R., Anderson P.S. Synthesis of a series of 4-(arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. J. Med. Chem. 37:1994;2437-2444.
39. Carroll S.S., Stahlhut M., Geib J., Olsen D.B. Inhibition of HIV-1 reverse transcriptase by a quinazolinone and comparison with inhibition by pyridinones. J. Biol. Chem. 269:1994;32351-32357.
40. Young S.D., Britcher S.F., Tran L.O., Payne L.S., Lumma W.C., Lyle T.A., Huff J.R., Anderson P.S., Olsen D.B., Carroll S.S., Pettibone D.J., O'Brien J.A., Ball R.G., Balani S.K., Lin J.H., Chen I.-W., Schleif W.A., Sardana V.V., Long W.J., Byrnes V.W., Emini E.A. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39:1995;2602-2605.
41. Kashman Y., Gustafson K.R., Fuller R.W., Cardellina J.H. II, McMahon J.B., Currens M.J., Buckheit R.W. Jr., Hughes S.H., Cragg G.M., Boyd M.R. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J. Med. Chem. 35:1992;2735-2743.
42. Zembower D.E., Liao S., Flavin M.T., Xu Z.-Q., Stup T.L., Buckheit R.W. Jr., Khilevich A., Mar A.A., Sheinkman A.K. Structural analogues of the calanolide anti-HIV agents. Modification of the trans-10,11-dimethyldihydropyran-12-ol ring (ring C). J. Med. Chem. 40:1997;1005-1017.
43. De Lucca G.V., Otto M.J. Synthesis and anti-HIV activity of pyrrolo-[1,2-d]-(1,4)-benzodiazepin-6-ones. Bioorg. Med. Chem. Lett. 2:1992;1639-1644.
44. Terrett N.K., Bojanic D., Merson J.R., Stephenson P.T. Imidazo[2′,3′:6,5]dipyrido[3,2-b:2′,3′-e]-1,4- diazepines: non-nucleoside HIV-1 reverse transcriptase inhibitors with greater enzyme affinity than nevirapine. Bioorg. Med. Chem. Lett. 2:1992;1745-1750.
45. Livermore D.G.H., Bethell R.C., Cammack N., Hancock A.P., Hann M.M., Green D.V.S., Lamont R.B., Noble S.A., Orr D.C., Payne J.J., Ramsay M.V.J., Shingler A.H., Smith C., Storer R., Williamson C., Willson T. Synthesis and anti-HIV-1 activity of a series of imidazo[1,5-b]pyridazines. J. Med. Chem. 36:1993;3784-3794.
46. Ijichi K., Fujiwara M., Hanasaki Y., Watanabe H., Katsuura K., Takayama H., Shirakawa S., Sakai S.-I., Shigeta S., Konno K., Yokota T., Baba M. Potent and specific inhibition of human immunodeficiency virus type 1 replication by 4-(2,6-dichlorophenyl)-1,2,5-thiadiazol-3-Y1 N,N-dialkylcarbamate derivatives. Antimicrob. Agents Chemother. 39:1995;2337-2340.
47. Ijichi K., Fujiwara M., Nagano H., Matsumoto Y., Hanasaki Y., Ide T., Katsuura K., Takayama H., Shirakawa S., Aimi N., Shigeta S., Konno K., Matsushima M., Yokota T., Baba M. Anti-HIV-1 activity of thiadiazole derivatives: a structure-activity relationship, reverse transcriptase inhibition, and lipophilicity. Antiviral Res. 31:1996;87-94.
48. Bellarosa D., Antonelli G., Bambacioni F., Giannotti D., Viti G., Nannicini R., Giachetti A., Dianzani F., Witvrouw M., Pauwels R., Desmyter J., De Clercq E. New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase. Antiviral Res. 30:1996;109-124.
49. Artico M., Massa S., Mai A., Marongiu M.E., Piras G., Tramontano E., La Colla P. 3,4-Dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs): a new class of specific inhibitors of human immunodeficiency virus type 1. Antiviral Chem. Chemother. 4:1993;361-368.
50. Massa S., Mai A., Artico M., Sbardella G., Tramontano E., Loi A.G., Scano P., La Colla P. Synthesis and antiviral activity of new 3,4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), specific inhibitors of human immunodeficiency virus type 1. Antiviral Chem. Chemother. 6:1995;1-8.
51. Dollé V., Nguyen C.H., Aubertin A.M., Kirn A., Andreola M.L., Jamieson G., Tarrago-Litvak L., Bisagni E. A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors. J. Med. Chem. 38:1995;4679-4686.
52. Jourdan F., Renault J., Fossey C., Bureau R., Ladurée D., Robba M., Aubertin A.M., Kirn A. Design, synthesis and antiviral activity of new pyridinone derivatives. Antiviral Chem. Chemother. 8:1997;161-172.
53. Kim D.-K., Gam J., Kim Y.-W., Lim J., Kim H.-T., Kim K.H. Synthesis and anti-HIV-1 activity of a series of 1-alkoxy-5-alkyl-6-(arylthio)uracils. J. Med. Chem. 40:1997;2363-2373.
54. Kelly T.A., McNeil D.W., Rose J.M., David E., Shih C.-K., Grob P.M. Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 6. 2-Indol-3-yl- and 2-azaindol-3-yl-dipyridodiazepinones. J. Med. Chem. 40:1997;2430-2433.
55. Campiani G., Nacci V., Fiorini I., De Filippis M.P., Garofalo A., Greco G., Novellino E., Altamura S., Di Renzo L. Pyrrolobenzothiazepinones and pyrrolobenzoxazepinones: novel and specific non-nucleoside HIV-1 reverse transcriptase inhibitors with antiviral activity. J. Med. Chem. 39:1996;2672-2680.
56. Antonucci T., Warmus J.S., Hodges J.C., Nickell D.G. Characterization of the antiviral activity of highly substituted pyrroles: a novel class of non-nucleoside HIV-1 reverse transcriptase inhibitor. Antiviral Chem. Chemother. 6:1995;98-108.
57. Althaus I.W., Chou K.-C., Lemay R.J., Franks K.M., Deibel M.R., Kezdy F.J., Resnick L., Busso M.E., So A.G., Downey K.M., Romero D.L., Thomas R.C., Aristoff P.A., Tarpley W.G., Reusser F. The benzylthio-pyrimidine U-31,355, a potent inhibitor of HIV-1 reverse transcriptase. Biochem. Pharmacol. 51:1996;743-750.
58. Barth B., Dierich M., Heinisch G., Jenny V., Matuszczak B., Mereiter K., Planer R., Schöpf I., Stoiber H., Traugott T., van Aufschnaiter P. Pyridazino[3,4-b][1,5]benzoxazepin-5(6H)-ones: synthesis and biological evaluation. Antiviral Chem. Chemother. 7:1996;300-312.
59. Krikorian D., Parushev S., Tarpanov V., Mechkarova P., Mikhova B., Botta M., Corelli F., Maga G., Spadari S. Synthesis and biological evaluation of imidazo[1,2-d][1,4]benzodiazepines and related compounds as potential anti-HIV-1 agents. Med. Chem. Res. 7:1997;546-556.
60. Di Santo R., Costi R., Artico M., Massa S., Marongiu M.E., Loi A.G., De Montis A., La Colla P. 1,2,5-Benzothiadiazepine and pyrrolo[2,1-d][1,2,5]benzo-thiadiazepine derivatives with specific anti-human immunodeficiency virus type 1 activity. Antiviral Chem. Chemother. 9:1998;127-137.
61. Silvestri R., Artico M., Bruno B., Massa S., Novellino E., Greco G., Marongiu M.E., Pani A., De Montis A., La Colla P. Synthesis and biological evaluation of 5H-indolo [3,2-b][1,5]benzothiazepine derivatives, designed as conformationally constrained analogues of the human immunodeficiency virus type 1 reverse transcriptase inhibitor L-737,126. Antiviral Chem. Chemother. 9:1998;139-148.
62. Wishka D.G., Graber D.R., Kopta L.A., Olmsted R.A., Friis J.M., Hosley J.D., Adams W.J., Seest E.P., Castle T.M., Dolak L.A., Keiser B.J., Yagi Y., Jeganathan A., Schlachter S.T., Murphy M.J., Cleek G.J., Nugent R.A., Poppe S.M., Swaney S.M., Han F., Watt W., White W.L., Poel T.-J., Thomas R.C., Voorman R.L., Stefanski K.J., Stehle R.G., Tarpley W.G., Morris J. (-)-6-Chloro-2-[(1-furo[2,3-c]pyridin-5-yl-ethyl)thio]-4-pyrimidinamine, PNU-142721, a new broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitor. J. Med. Chem. 41:1998;1357-1360.
63. L. Vrang, C. Ahgren, K. Ekelöf, P. Engelhardt, M. Högberg, R. Noréen, B. Öberg, C. Rydergard, C. Sahlberg, Anti-HIV activity of PETT-4 in vitro, Abs. 11th Int. Conf. Antiviral Res., San Diego, CA, USA, April 5-10, 1998, Antiviral Res. 37, Abs. no. 51, 1998, p. A55.
64. D.L. Taylor, P.S. Ahmed, A.S. Tyms, J. Bedard, J. Duchaine, G. Falardeau, J.F. Lavallee, M. Hamel, R.F. Rando, T. Bowlin, A pyrido [1,2a] indole derivative identified as a novel non-nucleoside reverse transcriptase inhibitor of HIV-1, Abs. 11th Int. Conf. Antiviral Res., San Diego, CA, USA, April 5-10, 1998, Antiviral Res. 37, Abs. no. 44, 1998, p. A53.
65. Fujiwara T., Sato A., El-Farrash M., Miki S., Abe K., Isaka Y., Kodama M., Wu Y., Chen L.B., Harada H., Sugimoto H., Hatanaka M., Hinuma Y. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 42:1998;13401345.
66. Witvrouw M., Arranz M.E., Pannecouque C., Declercq R., Jonckheere H., Schmit J.-C., Vandamme A.M., Diaz J.A., Ingate S.T., Desmyter J., Esnouf R., Van Meervelt L., Vega S., Balzarini J., De Clercq E. 1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4(thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors (NNRTIs) with anti-HIV-1 activity. Antimicrob. Agents Chemother. 42:1998;618-623.
67. E. Arranz, J.A. Díaz, S.T. Ingate, M. Witvrouw, C. Pannecouque, J. Balzarini, E. De Clercq, S. Vega, Novel 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives as non-nucleoside reverse transcriptase inhibitors that inhibit the human immunodeficiency virus type 1 (HIV-1) replication, J. Med. Chem. (1998), in press.
68. Pontikis R., Benhida R., Aubertin A.-M., Grierson D.S., Monneret C. Synthesis and anti-HIV activity of novel N-1 side chain-modified analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). J. Med. Chem. 40:1997;1845-1854.
69. Tanaka H., Walker R.T., Hopkins A.L., Ren J., Jones E.Y., Fujimoto K., Hayashi M., Miyasaka T., Baba M., Stammers D.K., Stuart D.I. Allosteric inhibitors against HIV-1 reverse transcriptase: design and synthesis of MKC-442 analogues having an ω-functionalized acyclic structure. Antiviral Chem. Chemother. 9:1998;325-332.
70. Tantillo C., Ding J., Jacobo-Molina A., Nanni R.G., Boyer P.L., Hughes S.H., Pauwels R., Andries K., Janssen P.A.J., Arnold E. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. J. Mol. Biol. 243:1994;369-387.
71. Debyser Z., Pauwels R., Baba M., Desmyter J., De Clercq E. Common features in the interaction of tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives with the human immunodeficiency virus type 1 reverse transcriptase. Mol. Pharmacol. 41:1992;963-968.
72. Dueweke T.J., Kézdy F.J., Waszak G.A., Deibel M.R. Jr., Tarpley W.G. The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase. J. Biol. Chem. 267:1992;27-30.
73. Spence R.A., Kati W.M., Anderson K.S., Johnson K.A. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science. 267:1995;988-993.
74. Ren J., Esnouf R., Garman E., Somers D., Ross C., Kirby I., Keeling J., Darby G., Jones Y., Stuart D., Stammers D. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Struct. Biol. 2:1995;293-302.
75. Esnouf R., Ren J., Ross C., Jones Y., Stammers D., Stuart D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Struct. Biol. 2:1995;303-308.
76. Ding J., Das K., Tantillo C., Zhang W., Clark A.D. Jr., Jesen S., Lu X., Hsiou Y., Jacobo-Molina A., Andries K., Pauwels R., Moereels H., Koymans L., Janssen P.A.J., Smith R.H. Jr., Kroeger Koepke M., Michejda C.J., Hughes S.H., Arnold E. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 Å resolution. Structure. 3:1995;365-379.
77. Ding J., Das K., Moereels H., Koymans L., Andries K., Janssen P.A.J., Hughes S.H., Arnold E. Structure of HIV-1 RT/TIBO R86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Struct. Biol. 2:1995;407-415.
78. Ren J., Esnouf R., Hopkins A., Ross C., Jones Y., Stammers D., Stuart D. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure. 3:1995;915-926.
79. Kroeger Smith M.B., Rouzer C.A., Taneyhill L.A., Smith N.A., Hughes S.H., Boyer P.L., Janssen P.A.J., Moereels H., Koymans L., Arnold E., Ding J., Das K., Zhang W., Michejda C.J., Smith R.H. Jr. Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity. Protein Sci. 4:1995;2203-2222.
80. Esnouf R.M., Ren J., Hopkins A.L., Ross C.K., Jones E.Y., Stammers D.K., Stuart D.I. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc. Natl. Acad. Sci. USA. 94:1997;3984-3989.
81. Pelemans H., Esnouf R.M., Parniak M.A., Vandamme A.-M., De Clercq E., Balzarini J. A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152. J. Gen. Virol. 79:1998;1347-1352.
82. Esnouf R.M., Stuart D.I., De Clercq E., Schwartz E., Balzarini J. Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives. Biochem. Biophys. Res. Commun. 234:1997;458-464.
83. Esnouf R.M. An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. J. Mol. Graph. 15:1997;132-134.
84. Schinazi R.F., Larder B.A., Mellors J.W. Mutations in retroviral genes associated with drug resistance. Int. Antiviral News. 5:1997;129-142.
85. Nunberg J.H., Schleif W.A., Boots E.J., O'Brien J.A., Quintero J.C., Hoffman J.M., Emini E.A., Goldman M.E. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J. Virol. 65:1991;4887-4892.
86. Richman D., Shih C.-K., Lowy I., Rose J., Prodanovich P., Goff S., Griffin J. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA. 88:1991;11241-11245.
87. Mellors J.W., Dutschman G.E., Im G.-J., Tramontano E., Winkler S.R., Cheng Y.-C. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol. Pharmacol. 41:1992;446-451.
88. Kleim J.-P., Bender R., Kirsch R., Meichsner C., Paessens A., Riess G. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase. Virology. 200:1994;696-701.
89. Kleim J.-P., Winkler I., Rösner M., Kirsch R., Rübsamen-Waigmann H., Paessens A., Riess G. In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitory HBY 097. Virology. 231:1997;112-118.
90. Kleim J.-P., Rösner M., Winkler I., Paessens A., Kirsch R., Hsiou Y., Arnold E., Riess G. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74→Val or Ile and Val-75→Leu or Ile) HIV-1 mutants. Proc. Natl. Acad. Sci. USA. 93:1996;34-38.
91. Boyer P.L., Gao H.-Q., Hughes S.H. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicrob. Agents Chemother. 42:1998;447-452.
92. Mellors J.W., Im G.-J., Tramontano E., Winkler S.R., Medina D.J., Dutschman G.E., Bazmi H.Z., Piras G., Gonzalez C.J., Cheng Y.-C. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)-imidazo[4,5,1-jk][1, 4]benzodiazepin-2(1H)-thione (TIBO R82150). Mol. Pharmacol. 43:1993;11-16.
93. 138→Lys on the p51 subunit. J. Biol. Chem. 269:1994;25255-25258.
94. Boyer P.L., Ding J., Arnold E., Hughes S.H. Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 38:1994;1909-1914.
95. Dueweke T.J., Pushkarskaya T., Poppe S.M., Swaney S.M., Zhao J.Q., Chen I.S.Y., Stevenson M., Tarpley W.G. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA. 90:1993;4713-4717.
96. Seki M., Sadakata Y., Yuasa S., Baba M. Isolation and characterization of human immunodeficiency virus type-1 mutants resistant to the non-nucleotide reverse transcriptase inhibitor MKC-442. Antiviral Chem. Chemother. 6:1995;73-79.
97. Buckheit R.W. Jr., Fliakas-Boltz V., Yeagy-Bargo S., Weislow O., Mayers D.L., Boyer P.L., Hughes S.H., Pan B.-C., Chu S.-H., Bader J.P. Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivaties is generated by mutations at multiple sites in the HIV-1 reverse transcriptase. Virology. 210:1995;186-193.
98. Balzarini J., Baba M., De Clercq E. Differential activities of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives against different human immunodeficiency virus type 1 mutant strains. Antimicrob. Agents Chemother. 39:1995;998-1002.
99. Balzarini J., Pérez-Pérez M.-J., Vélazquez S., San-Félix A., Camarasa M.-J., De Clercq E., Karlsson A. Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e. TSAO derivatives). Proc. Natl. Acad. Sci. USA. 92:1995;5470-5474.
100. Balzarini J., Pelemans H., Aquaro S., Perno C.-F., Witvrouw M., Schols D., De Clercq E., Karlsson A. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol. Pharmacol. 50:1996;394-401.
101. Pelemans H., Esnouf R., Dunkler A., Parniak M.A., Vandamme A.-M., Karlsson A., De Clercq E., Kleim J.-P., Balzarini J. Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1. J. Virol. 71:1997;8195-8203.
102. Balzarini J., Pelemans J.H., Esnouf R., De Clercq E. A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781. AIDS Res. Hum. Retrovir. 14:1998;255-260.
103. Richman D.D., Havlir D., Corbeil J., Looney D., Ignacio C., Spector S.A., Sullivan J., Cheeseman S., Barringer K., Pauletti D., Shih C.-K., Myers M., Griffin J. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1994;1660-1666.
104. Larder B.A. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 36:1992;2664-2669.
105. Byrnes V.W., Emini E.A., Schleif W.A., Condra J.H., Schneider C.L., Long W.J., Wolfgang J.A., Graham D.J., Gotlib L., Schlabach A.J., Wolanski B.S., Blahy O.M., Quintero J.C., Rhodes A., Roth E., Titus D.L., Sardana V.V. Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 38:1994;1404-1407.
106. Balzarini J., Pelemans H., Riess G., Roesner M., Winkler I., De Clercq E., Kleim J.-P. Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine. J. Infect. Dis. 176:1997;1392-1397.
107. Balzarini J., Pelemans H., Riess G., Roesner M., Winkler I., De Clercq E., Kleim J.-P. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-dihydroquinoxaline- 2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2′,3′-dideoxy-3′-thiacytidine (lamivudine). Biochem. Pharmacol. 55:1998;617-625.
108. Wainberg M.A., Drosopoulos W.C., Salomon H., Hsu M., Borkow G., Parniak M.A., Gu Z., Song Q., Manne J., Islam S., Castriota G., Prasad V.R. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science. 271:1996;1282-1285.
109. Balzarini J., Pelemans H., Karlsson A., De Clercq E., Kleim J.-P. Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors. Proc. Natl. Acad. Sci. USA. 93:1996;13152-13157.
110. Buckheit R.W. Jr., White E.L., Germany-Decker J., Allen L.B., Ross L.J., Shannon W.M., Janssen P.A.J., Chirigos M.A. Cell-based and biochemical analysis of the anti-HIV activity of combinations of 3′-azido-3′-deoxythymidine and analogues of TIBO. Antiviral Chem. Chemother. 5:1994;35-42.
111. Richman D., Rosenthal A.S., Skoog M., Eckner R.J., Chou T.-C., Sabo J.P., Merluzzi V.J. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob. Agents Chemother. 35:1991;305-308.
112. Chong K.-T., Pagano P.J., Hinshaw R.R. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azido-3′-deoxythymidine or 2′,3′-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob. Agents Chemother. 38:1994;288-293.
113. Brennan T.M., Taylor D.L., Bridges C.G., Leyda J.P., Tyms A.S. The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds. Antiviral Res. 26:1995;173-187.
114. Yuasa S., Sadakata Y., Takashima H., Sekiya K., Inouye N., Ubasawa M., Baba M. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442. Mol. Pharmacol. 44:1993;895-900.
115. Pagano P.J., Chong K.-T. In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-α J. Infect. Dis. 171:1995;61-71.
116. Ito M., Baba M., Shigeta S., De Clercq E., Walker R.T., Tanaka H., Miyasaka T. Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by 1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine (HEPT) and recombinant α-interferon. Antiviral Res. 15:1991;323-330.
117. E. Hill, N. Taylor, K. Borroto-Esoda, P. Furman, C. Moxhan, G. Painter, In vitro synergy studies with MKC-442, a non-nucleoside HIV-1 reverse transcriptase inhibitor, Abs. 11th Int. Conf. Antiviral Res., San Diego, CA, USA, April 5-10, 1998, Antiviral Res. 37, Abs. no. 49, 1998, p. A54.
118. Balzarini J., De Clercq E. The thiocarboxanilides UC-10 and UC-781 have an additive inhibitory effect against human immunodeficiency virus type 1 reverse transcriptase and replication in cell culture when combined with other antiretroviral drugs. Antiviral Chem. Chemother. 8:1997;197-204.
119. Okamoto M., Makino M., Yamada K., Nakade K., Yuasa S., Baba M. Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1-infected cells. Antiviral Res. 31:1996;69-77.
120. Balzarini J., Pelemans H., Pérez-Pérez M.-J., San-Félix A., Camarasa M.-J., Karlsson A. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2′,3′-dideoxy-3′-thiacytidine. Mol. Pharmacol. 49:1996;882-890.
121. Staszewski S., Massari F.E., Kober A., Gohler R., Durr S., Anderson K.W., Schneider C.L., Waterbury J.A., Bakshi K.K., Taylor V.I., Hildebrand C.S., Kreisl C., Hoffstedt B., Schleif W.A., von Briesen H., Rübsamen-Waigmann H., Calandra G.B., Ryan J.L., Stille W., Emini E.A., Byrnes V.W. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high level resistance to L-697,661, a non-nucleoside reverse transcriptase inhibitor. J. Infect. Dis. 171:1995;159-165.
122. Staszewski S., Miller V., Rehmet S., Stark T., De Creé J., De Brabander M., Peeters M., Andries K., Moeremans M., De Raeymaeker M., Pearce G., Van Den Broeck R., Verbiest W., Stoffels P. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS. 10:1996;F1-F7.
123. Schooley R.T., Campbell T.B., Kuritzkes D.R., Blaschke T., Stein D.S., Rosandich M.E., Phair J., Pottage J.C., Messari F., Collier A., Kahn J. Phase 1 study of combination therapy with L-697,661 and zidovudine. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 12:1996;363-370.
124. Carr A., Vella S., de Jong M.D., Sorice F., Imrie A., Boucher C.A., Cooper D.A. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. AIDS. 10:1996;635-641.
125. Davey R.T. Jr., Chaitt D.G., Reed G.F., Freimuth W.W., Herpin B.R., Metcalf J.A., Eastman P.S., Falloon J., Kovacs J.A., Polis M.A., Walker R.E., Masur H., Boyle J., Coleman S., Cox S.R., Wathen L., Daenzer C.L., Lane H.C. Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 40:1996;1657-1664.
126. D'Aquila R.T., Hughes M.D., Johnson V.A., Fischl M.A., Sommadossi J.-P., Liou S.-h., Timpone J., Myers M., Basgoz N., Niu M., Hirsch M.S. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 124:1996;1019-1030.
127. Luzuriaga K., Bryson Y., Krogstad P., Robinson J., Stechenberg B., Lamson M., Cort S., Sullivan J.L. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. New Engl. J. Med. 336:1997;1343-1349.
128. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet. 349:1997;1413-1421.
129. Balzarini J., Karlsson A., Pérez-Pérez M.-J., Camarasa M.-J., De Clercq E. Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. Virology. 196:1993;576-585.
130. Vasudevachari M.B., Battista C., Lane H.C., Psallidopoulos M.C., Zhao B., Cook J., Palmer J.R., Romero D.L., Tarpley W.G., Salzman N.P. Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors. Virology. 190:1992;269-277.
131. Balzarini J., Karlsson A., Meichsner C., Paessens A., Riess G., De Clercq E., Kleim J.-P. Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720. J. Virol. 68:1994;7986-7992.
132. Winslow D.L., Garber S., Reid C., Scarnati H., Baker D., Rayner M.M., Anton E.D. Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. AIDS. 10:1996;1205-1209.
133. Grob P.M., Cao Y., Muchmore E., Ho D.D., Norris S., Pav J.W., Shih C.-K., Adams J. Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase. Nat. Med. 3:1997;665-670.
134. Pialoux G., Youle M., Dupont B., Gazzard B., Cauwenbergh G.F.M.J., Stoffels P.A.M., Davies S., De Saint Martin J., Janssen P.A.J. Pharmacokinetics of R 82913 in patients with AIDS or AIDS-related complex. Lancet. 338:1991;140-143.
135. De Wit S., Hermans P., Sommereijns B., O'Doherty E., Westenborghs R., Van De Velde V., Cauwenbergh G.F.M.J., Clumeck N. Pharmacokinetics of R 82913 in AIDS patients: a phase I dose-finding study of oral administration compared with intravenous infusion. Antimicrob. Agents Chemother. 36:1992;2661-2663.
136. Davey R.T. Jr., Dewar R.L., Reed G.F., Vasudevachari M.B., Polis M.A., Kovacs J.A., Falloon J., Walker R.E., Masur H., Haneiwich S.E., O'Neill D.G., Decker M.R., Metcalf J.A., Deloria M.A., Laskin O.L., Salzman N., Lane H.C. Plasma viremia as a sensitive indicator of the antiretroviral activity of L-697,661. Proc. Natl. Acad. Sci. USA. 90:1993;5608-5612.
137. Saag M.S., Emini E.A., Laskin O.L., Douglas J., Lapidus W.I., Schleif W.A., Whitley R.J., Hildebrand C., Byrnes V.W., Kappes J.C., Anderson K.W., Massari F.E., Shaw G.M. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. New Engl. J. Med. 329:1993;1065-1072.
138. Havlir D., Cheeseman S.H., McLaughlin M., Murphy R., Erice A., Spector S.A., Greenough T.C., Sullivan J.L., Hall D., Myers M., Lamson M., Richman D.D. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J. Infect. Dis. 171:1995;537-545.
139. Staszewski S., Miller V., Kober A., Colebunders R., Vandercam B., Delescluse J., Clumeck N., Van Wanzeele F., De Brabander M., De Creé J., Moeremans M., Andries K., Boucher C., Stoffels P., Janssen P.A.J. Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients. Antiviral Ther. 1:1996;42-50.
140. C.P. Moxham, K. Borroto-Esoda, D. Noel, P.A. Furman, G.M. Szczech, D.W. Barry, Preliminary efficacy, pharmacokinetics and safety of repeated multiple doses of MKC-442 in HIV-infected volunteers, Abs. 10th Int. Conf. Antiviral Res., Atlanta, GA, USA, April 6-11, 1997, Antiviral Res. 34, Abs. no. 2, 1997, A44.
141. Rübsamen-Waigmann H., Huguenel E., Paessens A., Kleim J.-P., Wainberg M.A., Shah A. Second-generation non-nucleoside reverse transcriptase inhibitor HBY 097 and HIV-1 viral load. Lancet. 349:1997;1517.
142. De Jong M.D., Vella S., Carr A., Boucher C.A.B., Imrie A., French M., Hoy J., Sorice S., Pauluzzi S., Chiodo F., Weverling G.J., van der Ende M.E., Frissen Ph.J., Weigel H.M., Kauffmann R.H., Lange J.M.A., Yoon R., Moroni M., Hoenderdos E., Leitz G., Cooper D.A., Hall D., Reiss P. High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. J. Infect. Dis. 175:1997;966-970.
143. 3: AIDS clinical trials group protocol 208. J. Infect. Dis. 172:1995;1379-1383.
144. Marschner I.C., Collier A.C., Coombs R.W., D'Aquila R.T., DeGruttola V., Fischl M.A., Hammer S.M., Hughes M.D., Johnson V.A., Katzenstein D.A., Richman D.D., Smeaton L.M., Spector S.A., Saag M.S. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J. Infect. Dis. 177:1998;40-47.
145. Havlir D.V., Richman D.D. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann. Intern. Med. 124:1996;984-994.
146. Perrin L., Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science , -1873. 280:1871;1998.
147. Wei X., Ghosh S.K., Taylor M.E., Johnson V.A., Emini E.A., Deutsch P., Lifson J.D., Bonhoeffer S., Nowak M.A., Hahn B.H., Saag M.S., Shaw G.M. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 373:1995;117-122.
148. Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 373:1995;123-126.
149. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., Ho D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 271:1996;1582-1586.
150. Cao Y., Qin L., Zhang L., Safrit J., Ho D.D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. New Engl. J. Med. 332:1995;201-208.
151. Pantaleo G., Menzo S., Vaccarezza M., Graziosi C., Cohen O.J., Demarest J.F., Montefiori D., Orenstein J.M., Fox C., Schrager L.K., Margolick J.B., Buchbinder S., Giorgi J.V., Fauci A.S. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. New Engl. J. Med. 332:1995;209-216.
152. O'Brien W.A., Hartigan P.M., Martin D., Esinhart J., Hill A., Benoit S., Rubin M., Simberkoff M.S., Hamilton J.D. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. New Engl. J. Med. 334:1996;426-431.
153. Saag M.S., Holodniy M., Kuritzkes D.R., O'Brien W.A., Coombs R., Poscher M.E., Jacobsen D.M., Shaw G.M., Richman D.D., Volberding P.A. HIV viral load markers in clinical practice. Nat. Med. 2:1996;625-629.
154. Mellors J.W., Rinaldo C.R. Jr., Gupta P., White R.M., Todd J.A., Kingsley L.A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 272:1996;1167-1170.
155. Craib K.J.P., Strathdee S.A., Hogg R.S., Leung B., Montaner J.S.G., O'Shaughnessy M.V., Schechter M.T. Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection. J. Infect. Dis. 176:1997;798-800.
156. Wong J.K., Hezareh M., Günthard H.F., Havlir D.V., Ignacio C.C., Spina C.A., Richman D.D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 278:1997;1291-1295.
157. Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E., Quinn T.C., Chadwick K., Margolick J., Brookmeyer R., Gallant J., Markowitz M., Ho D.D., Richman D.D., Siliciano R.F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 279:1997;1295-1300.